Brought to you by 
Synthetic biology company Intrexon acquires protein therapeutics company ActoGeniX
10 Sep 2020
Executive Summary
Intrexon Corp. (synthetic biology) acquired ActoGeniX NV (protein therapies) for approximately $30mm in cash plus $30mm in stock (via the issuance of 965k shares). The transaction is expected to close in Q1 2015.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Synthetic biology company Intrexon acquires protein therapeutics company ActoGeniX
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice